RNU6-925P

Across TCGA pan-cancer cohorts, RNU6-925P RNA differs between tumor and matched normal tissue in 10 of 18 cancer types tested, making tumor–normal expression one of RNU6-925P’s most consistent transcriptional readouts.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where RNU6-925P RNA is more highly expressed in tumor relative to normal tissue. In most cancer types RNU6-925P is over-expressed in tumor, although a few such as KIRC and KICH show the opposite, repressed pattern.

BLCA, KIRP, and STAD are the cancer types where RNU6-925P tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RNU6-925P RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BLCA	Female	III,IV	+1.217	<.001	7	view →
KIRP	All	IV	+1.387	.006	6	view →
STAD	All	All	+0.880	.001	6	view →
KIRC	All	All	−0.379	.002	5	view →
KICH	All	All	−0.516	.013	3	view →
LIHC	All	All	+0.361	.003	3	view →
CHOL	All	All	+1.595	<.001	2	view →
PAAD	Female	All	+0.790	.014	2	view →
HNSC	Male	III,IV	+0.643	.027	1	view →
THCA	Male	All	−0.390	.026	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 10 strongest of 10 lineages.

RNU6-925P–BLCA

Open the BLCA breakdown →